Immutep has revealed encouraging initial clinical data from two trials investigating its lead product candidate eftilagimod alpha in non-small-cell lung cancer. Findings from the trials were shared at the Society for Immunotherapy of Cancer (SITC) Annual Meeting 2022. The INSIGHT-003 trial is evaluating eftilagimod alpha as part of a triple combination therapy with standard-of-care anti-PD-1 […]
Menu ≡ ╳ 
